Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.

Empagliflozin in Patients with Chronic Kidney Disease

Open access
The EMPA-KIDNEY Collaborative Group · 2023 · New England Journal of Medicine

Abstract

Trial of empagliflozin in a broad chronic kidney disease population.

Overview

CoChat Summary

TL;DR

Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.

Key findings

  • The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
  • All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
  • There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
  • Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).

Methods

  • Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
  • Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
  • Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.

Limitations

  • The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
  • Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
  • Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2204233

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The primary outcome of kidney disease progression or death from cardiovascular causes occurred in 432 participants (13.1%) in the empagliflozin group and 558 participants (16.9%) in the placebo group. This represented 42 fewer primary outcomes per 1000 patients treated for 2 years.
Figure 1 The primary outcome of kidney disease progression or death from cardiovascular causes occurred in 432 participants (13.1%) in the empagliflozin group and 558 participants (16.9%) in the placebo group. This represented 42 fewer primary outcomes per 1000 patients treated for 2 years.CC BY-ND · PubMed Central
Figure 2 The primary outcome of kidney disease progression or death from cardiovascular causes occurred in 432 participants (13.1%) in the empagliflozin group and 558 participants (16.9%) in the placebo group. This represented 42 fewer primary outcomes per 1000 patients treated for 2 years.
Figure 2 The primary outcome of kidney disease progression or death from cardiovascular causes occurred in 432 participants (13.1%) in the empagliflozin group and 558 participants (16.9%) in the placebo group. This represented 42 fewer primary outcomes per 1000 patients treated for 2 years.CC BY-ND · PubMed Central
Figure 3 Effect of allocation to empagliflozin on estimated glomerular filtration rate Shown are forest plots of the hazard ratios for the primary outcome according to key prespecified baseline subgroups (with the diamond representing the overall result). Hazard ratios, confidence intervals, and P values were estimated with the use of Cox proportional-hazards regression models, adjusted for age, sex, prior diabetes, estimated glomerular filtration rate (GFR), urinary albumin-to-creatinine ratio (ACR) and region. Tests for heterogeneity or trend in the hazard ratio for subgroups were estimated through the inclusion of relevant interaction terms. Error bars presented are 95% confidence intervals.
Figure 3 Effect of allocation to empagliflozin on estimated glomerular filtration rate Shown are forest plots of the hazard ratios for the primary outcome according to key prespecified baseline subgroups (with the diamond representing the overall result). Hazard ratios, confidence intervals, and P values were estimated with the use of Cox proportional-hazards regression models, adjusted for age, sex, prior diabetes, estimated glomerular filtration rate (GFR), urinary albumin-to-creatinine ratio (ACR) and region. Tests for heterogeneity or trend in the hazard ratio for subgroups were estimated through the inclusion of relevant interaction terms. Error bars presented are 95% confidence intervals.CC BY-ND · PubMed Central

Verification

Claims the paper makes

10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations

17 more claims

Create a free account to see all 54 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Staplin N, Haynes R, Mayne K, et al. Impact of diabetes on the effects of sodium glucose cotransporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (in press).

Cited by

See all 2,754

Metadata

Authors
The EMPA-KIDNEY Collaborative Group
Corresponding author
The EMPA-KIDNEY Collaborative Group
Venue
New England Journal of Medicine
Published
2023-01-12
Volume
388
Issue
2
Pages
117-127
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4308183941
Cited by
2,754
References
26
Citations by year
2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
FWCI
321.13
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nd)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
  • Hispana (submittedVersion, cc-by-nd)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • Bristol Research (University of Bristol) (submittedVersion)
  • Explore Bristol Research (submittedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Funders
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • NIHR Biomedical Centre, Oxford
  • Health Data Research
  • Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
  • Kidney Research UK (MR/R007764/1)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empagliflozin in Patients with Chronic Kidney Disease. https://app.cochat.ai/papers/10.1056/nejmoa2204233
The paper
The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2204233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.